MEMBER LOGIN: Your Email: Password: Remember Me
Forgot Your Password or would like to register?
BMY Bristol-Myers Squ
As Of 6/19/2018 8:04:00 AM
Current Price$53.65
Current Rating8
Return Since 7/2015
Bristol-Myers Squ -19.37 %
S&P 50034.35 %
VFS Rating Analysis
Related Links
Company News
Earnings Call Transcripts
Options Chain
Options Pricing History
For current estimates, historical performance information and more, Log in to your account.

Monthly Performance and Prediction History
Below is the monthly performance history for this security and the monthly change as compared to the stock market for this security. When a row is highlighted in green, it is identifying a stock that the model predict will outperform the portfolio for that month. When a row is highlighted in red, it is identifying a stock that the model predicted will underperform for the month. No highlight indicates the model is neutral on the stock. These predictions are always recorded at the beginning of the month, and table below shows the resulting return for the month.
DateVFS RatingPredictionRating PriceSubsequent
Month
% Increase
Subsequent
Month
Market %
Increase *
Return
vs
market
6-01-20187 $52.62   
* As measured by the performance of the S&P 500 for the month.

RECENT COMPANY NEWS
SymbolsWt.TitleDate
BMY13Bristol-Myers Posts Data on Empliciti, China Approves Opdivo (finance.yahoo.com)6/18/2018 3:23:00 PM
BMY13Does Bristol-Myers Squibb Company’s (NYSE:BMY) PE Ratio Signal A Selling Opportunity? (finance.yahoo.com)6/12/2018 2:32:00 PM
BMY13See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. (finance.yahoo.com)6/8/2018 5:01:00 AM
BMY13Bristol-Myers (BMY) Reports Data from CheckMate-214 Study (finance.yahoo.com)6/5/2018 3:08:00 AM
BMY8Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma (finance.yahoo.com)6/17/2018 3:30:00 AM
BMY8China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) (finance.yahoo.com)6/15/2018 5:32:00 AM
BMY8Bristol-Myers Squibb Announces Dividend (finance.yahoo.com)6/14/2018 1:30:00 PM
BMY8Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) (finance.yahoo.com)6/13/2018 3:00:00 AM
BMY8Bristol-Myers Squibb to Take Part in Goldman Sachs 39th Annual Global Healthcare Conference (finance.yahoo.com)6/11/2018 1:45:00 PM
BMY8Bristol-Myers Squibb to Announce Results for Second Quarter 2018 on July 26 (finance.yahoo.com)6/7/2018 3:59:00 AM
BMY8Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study (finance.yahoo.com)6/5/2018 5:42:00 AM
BMY8Do Nektar’s disappointing clinical trial results invalidate $2 billion Bristol-Myers deal? (finance.yahoo.com)6/5/2018 5:13:00 AM
BMY3Eight Stocks That Are Poised to Change Direction (finance.yahoo.com)6/18/2018 12:00:00 PM
BMY35 Drug Stocks With Fat Payouts (finance.yahoo.com)6/18/2018 3:00:00 AM
BMY3Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers (finance.yahoo.com)6/15/2018 11:31:00 AM
BMY3Fred Hutch leases iconic Lake Union Steam Plant facility (finance.yahoo.com)6/11/2018 6:30:00 AM
BMY3The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie (finance.yahoo.com)6/11/2018 6:08:00 AM
BMY3Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant (finance.yahoo.com)6/8/2018 7:27:00 AM
BMY3Why Nektar Therapeutics Stock Stumbled 11.8% Today (finance.yahoo.com)6/7/2018 6:09:00 PM
BMY3Here's Why Nektar Therapeutics Jumped as Much as 17% Today (finance.yahoo.com)6/6/2018 1:15:00 PM
BMY3ASCO Ends: Winners & Losers at the Key Cancer Research Event (finance.yahoo.com)6/6/2018 5:29:00 AM
BMY3Nektar Therapeutics Stock Is a Buy After a Major Market Misread (finance.yahoo.com)6/5/2018 8:00:00 AM

WEBSITE DISCLAIMER:  Puget Investors and Vertical Financial Systems, Inc are not registered investment advisers, broker/dealers, or research analysts/organizations. The content on this website is issued solely for information purposes and should not to be construed as an offer to buy, sell, or trade in any way, any security mentioned herein.

All information presented on this website is believed to be reliable and written in good faith, but no representation or warranty, expressed or implied is made as to their accuracy, completeness or correctness. You are responsible for doing your own research before investing in any securities mentioned herein. Readers are urged to consult with their own independent financial advisors with respect to any investment. Neither Vertical Financial Systems, Inc, nor its officers or employees accept any liability whatsoever for any direct or consequential loss arising from any use of information on this website.

Past performance is not a guarantee of future performance or accuracy. Rating calculations and methodology may change at any time, and we reserve the right to make changes which may impact the accuracy of the model without prior notice to anybody.

Be advised that employees and officers of Vertical Financial Systems, Inc and Pugetinvestor.com may hold positions in the securities mentioned in this website.
Website Operated by Vertical Financial Systems, Inc